search icon
  • Print
  • ShareThis
  • Text Size
  • NIH Member Spotlight: Dr. C. Buddy Creech

    Principal Investigator, Vaccine and Treatment Evaluation Unit, Vanderbilt University, Nashville, TN

    Dr. Buddy Creech serves as Director of the Vanderbilt Vaccine Research Program (VVRP) and oversees the NIH-funded VVRP Vaccine Treatment and Evaluation Unit (VTEU), one of only nine VTEU sites in the U.S. He leads trials in vaccines targeting malaria, influenza, and other pathogens of childhood.

    During his pediatric infectious diseases fellowship, Dr. Creech became part of the Vanderbilt Clinical Research Scholars Program, a competitive NIH K12 award for young investigators.

    Dr. Creech’s NIH Supported Research

    Established by NIAID in 1962, VTEUs are frequently called upon to evaluate high-profile vaccine candidates, such as those targeting malaria, smallpox and pertussis. The VTEU system is also a vital component of pandemic influenza preparedness.

    Dr. Creech has served as principal investigator for numerous VTEU studies, including:

    • a Phase I malaria vaccine study
    • studies of live-attenuated influenza vaccines in children
    • a randomized, placebo-controlled trial of antibiotics in the treatment of skin and soft tissue infections

    Impact on Patients and Public Health

    VTEUs have played a key role in the NIAID effort to develop new and improved vaccines and therapies against infectious diseases. VTEUs:

    • improve rapid-response capabilities for emerging threats
    • test novel vaccines and delivery systems
    • strengthen national biodefense

    VTEUs have conducted hundreds of clinical trials for critically important childhood vaccines that have saved countless lives. Their work is essential to public health on a national and global scale.

| HIVMA | Contact Us

© Copyright IDSA 2018 Infectious Diseases Society of America

Full Site Mobile Site